Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells
Longeveron Inc. - Class A Common stock (LGVN)
Company Research
Source: PR Newswire
AVAI, LCTX, OCGN, VRTX, and LGVN Advance Cell-Based and Gene-Therapy Approaches to Age-Related DiseaseIssued on behalf of Avaí Bio, Inc.Companies mentioned in this article: Avaí Bio, Inc. (OTCQB: AVAI), Lineage Cell Therapeutics, Inc. (NYSE American: LCTX), Ocugen, Inc. (NASDAQ: OCGN), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Longeveron Inc. (NASDAQ: LGVN)Key Takeaways:Avaí Bio (OTCQB: AVAI) and its joint venture partner Austrianova announced on April 7, 2026, that they will present their latest data from their a-Klotho anti-aging therapy at the Second Annual Klotho Conference in September, alongside Dr. Makoto Kuro-o — the physician-scientist widely recognized for discovering the Klotho gene [1]."Klothonova," AVAI's joint venture company with Austrianova, is applying its clinically-validated Cell-in-a-Box® encapsulation platform to protect the genetically modified cells inside that overexpress a-Klotho, the longevity protein whose circulating levels decline sharply with ag
Show less
Read more
Impact Snapshot
Event Time:
LGVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LGVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LGVN alerts
High impacting Longeveron Inc. - Class A Common stock news events
Weekly update
A roundup of the hottest topics
LGVN
News
- Longeveron (LGVN) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=LGVN&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> to "hold".MarketBeat
- Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)GlobeNewswire
- A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.PR Newswire
- Longeveron (LGVN) Q4 2025 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Longeveron Inc. (LGVN) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
LGVN
Earnings
- 3/17/26 - Miss
LGVN
Sec Filings
- 4/20/26 - Form EFFECT
- 4/17/26 - Form 424B3
- 4/10/26 - Form 8-K
- LGVN's page on the SEC website